HIPEC and Cytoreductive Surgery for Peritoneal Mesothelioma: Who Qualifies and What to Expect
Cytoreductive surgery with HIPEC has changed peritoneal mesothelioma outcomes. Who qualifies, what the published data show, and what recovery involves.
Articles by James
Mesothelioma Clinical Trial Enrollment: A Practical Guide to Finding, Decoding, and Joining a Trial
How to find a mesothelioma clinical trial, read the listing, decode the eligibility criteria, and understand what enrolling actually involves.
First-Line Mesothelioma Treatment in 2026: How to Choose Between Nivolumab+Ipilimumab and Pembrolizumab+Chemo
Two immunotherapy regimens are now first-line for unresectable pleural mesothelioma. Here is what each trial showed and how the decision is framed.
Second-Line Mesothelioma Treatment: When First-Line Stops Working, What Comes Next
When first-line mesothelioma treatment fails, the next decision is rarely between two clear options. Here is what the primary trial evidence supports.
Pleurectomy/Decortication vs Extrapleural Pneumonectomy: How Mesothelioma Surgery Decisions Are Made
Two operations dominate the mesothelioma surgical conversation. Here is what the trials, the meta-analyses, and the high-volume centers actually say.
ECOG Performance Status and Other Prognostic Factors in Mesothelioma: What the Numbers Mean for Your Options
ECOG, CALGB, EORTC, and the Brims model translate clinical reality into trial eligibility and prognosis. Here is what each score actually measures.
Mesothelioma Survival Rates by Stage and Histology: What the Trial Data Actually Show
Mesothelioma survival numbers by stage and histology from SEER, IASLC, and modern trial data. What the statistics mean, and what they leave out.
Stage 1 Pleural Mesothelioma: Operable Disease and the Multimodal Treatment Window
For someone newly told their pleural mesothelioma is stage 1: what the AJCC criteria mean and how multimodal therapy is sequenced around surgery.
Stage 2 Pleural Mesothelioma: Borderline-Operable Disease and the Induction-Therapy Decision
Stage 2 pleural mesothelioma sits at the borderline of operable disease. Here is what the AJCC criteria mean and how the induction-therapy decision is framed.
Stage 3 Pleural Mesothelioma: Inoperable Disease, Immunotherapy, and the Active Trial Landscape
Stage III pleural mesothelioma in 2026: what AJCC IIIA and IIIB mean, why most cases are inoperable, and the immunotherapy and trial options.
Mesothelioma Chest Pain: How It Differs from Cardiac, Pleural, and Muscular Causes
Mesothelioma chest pain is usually dull, lateralized, and persistent. How it differs from cardiac, pleural, and chest wall causes.
Mesothelioma Early Warning Signs: What to Notice 20 to 50 Years After Asbestos Exposure
Mesothelioma takes decades to surface after asbestos exposure. The earliest signs are quiet. Here is what the primary clinical literature documents.
The Mesothelioma Symptom Timeline: From Latency to Late-Stage Progression
Mesothelioma unfolds over decades. Here is the chronological arc the primary clinical literature documents, from asbestos exposure to late-stage disease.
Pleural Effusion in Mesothelioma: Drainage, Recurrence, and What It Means for Prognosis
Most people with pleural mesothelioma present with fluid in the chest. What the clinical literature says about drainage, recurrence, and prognosis.
Stage 4 Mesothelioma: What to Expect and How Late-Stage Symptoms Are Managed
Clinical guide for families with someone in stage 4 mesothelioma: what AJCC staging means, what symptoms to expect, and how oncology teams manage them.
Asbestos Trust Funds for Louisiana Workers
How Louisiana shipyard, refinery, and longshore workers file asbestos trust claims. Key trusts for Avondale and Mississippi River corridor exposure.
Louisiana Mesothelioma Verdicts and Settlements: Avondale, Take-Home, and the Virile Share
Verified Louisiana verdicts include the $36.7M Walker chemical corridor case (affirmed at $35.75M), Pete v. Ports America (reduced to $5M), and $7M Williams.
Asbestos Trust Funds for New Jersey Workers
How New Jersey shipyard, refinery, and Manville plant workers can file asbestos trust fund claims. Johns-Manville, W.R. Grace, and related trusts.
Kroger, Contractor Pay $108K for Asbestos in Open Taylorville Store
Kroger and contractor SSI Services pay $108K to Illinois AG after leaving chipped asbestos floor tiles in public areas of an open Taylorville store.
Wisconsin Supreme Court Upholds $26.5M Pabst Asbestos Verdict
Wisconsin Supreme Court affirms $26.5M verdict against Pabst for steamfitter Jerry Lorbiecki's mesothelioma death, rejecting its contractor defense.
Asbestos Trust Funds for Washington Workers
How Washington shipyard, paper mill, aluminum, and construction workers can file asbestos trust fund claims. Key trusts and process.
Washington Mesothelioma Verdicts and Settlements
Washington mesothelioma outcomes: $13.5M Longview Fibre paper mill verdict, $16.2M Kotzerke default judgment, Budd v. Kaiser Gypsum, and 2025 appellate rulings.
Asbestos Trust Funds for Alabama Workers
Alabama industrial history, state appellate precedent, and national 524(g) trusts that compensate Alabama workers exposed to asbestos.
Asbestos Trust Funds for Michigan Workers
How Michigan auto workers and tradespeople file asbestos trust claims. Wayne County master docket, MI statute of limitations, Federal-Mogul Trust.
Asbestos Trust Funds for Missouri Workers
How Missouri manufacturing workers, mechanics, and railroad employees can file asbestos trust fund claims. Key trusts and eligibility.
Asbestos Trust Funds for Ohio Workers
How Ohio steelworkers, auto workers, and pipefitters can file asbestos trust fund claims. Key trusts, eligibility, and filing process.
Asbestos Trust Funds for Wisconsin Workers
How Wisconsin paper mill workers, manufacturers, and shipyard workers can file asbestos trust fund claims. Key trusts and filing process.
Asbestos Trust Funds for California Workers
How California shipyard workers, refinery workers, and construction tradespeople can file asbestos trust fund claims. Key trusts and filing process.
Asbestos Trust Funds for Florida Workers
How Florida shipyard workers, military base personnel, and construction workers can file asbestos trust fund claims. Key trusts and process.
Asbestos Trust Funds for Indiana Workers
How Indiana steelworkers, auto workers, and power plant employees can file asbestos trust fund claims. Key trusts and filing process.
Asbestos Trust Funds for Pennsylvania Workers
How Pennsylvania steel mill workers, shipyard workers, and construction tradespeople can file asbestos trust fund claims. Key trusts and process.
Asbestos Trust Funds for Tennessee Workers
How Tennessee chemical plant workers, Oak Ridge employees, and manufacturing workers can file asbestos trust fund claims.
Asbestos Trust Funds for Georgia Workers
How Georgia shipyard workers, paper mill employees, and construction tradespeople can file asbestos trust fund claims. Key trusts and filing process.
Asbestos Trust Funds for Iowa Workers
How Iowa manufacturing, meatpacking, and agricultural equipment workers can file asbestos trust fund claims. Key trusts and filing process.
Asbestos Trust Funds for New York Workers
How New York shipyard workers, construction tradespeople, and 9/11 responders can file asbestos trust fund claims. Key trusts and filing process.
Asbestos Trust Funds for Illinois Workers
Asbestos trust funds for Illinois workers: Madison and St. Clair venue history, IL Supreme Court precedent, and 2-year SOL under 735 ILCS 5/13-202.
$3.9 Million and the Great Lakes: Michigan Mesothelioma Verdicts
Verified mesothelioma verdicts and settlements involving Michigan workers, from Great Lakes shipping to Midland chemical plant exposure.
$20 Million and Counting: Missouri Mesothelioma Verdicts
St. Louis leads Missouri in asbestos jury awards. Key verdicts and what they mean for Missouri families with mesothelioma.
$27.5 Million and Counting: Ohio Mesothelioma Verdicts
Cuyahoga County leads Ohio in mesothelioma jury awards. Key verdicts and what they mean for Ohio families pursuing asbestos claims.
Wisconsin Mesothelioma Verdicts and Settlements
Key mesothelioma verdicts and settlement outcomes in Wisconsin, including the Pabst Brewing safe-place ruling and the Krentz take-home exposure verdict.
California Mesothelioma Verdicts and Settlements
Two named California mesothelioma outcomes: the $33.4M Stephenson v. Mole-Richardson result and the $51M Chapman v. Avon judgment affirmed on appeal.
Florida Mesothelioma Verdicts and Settlements
Documented Florida mesothelioma verdicts, from J&J talc to secondhand brake dust, with Fla. Stat. § 95.11 filing deadlines and appellate status notes.
Indiana Mesothelioma Verdicts and Settlements
Indiana mesothelioma litigation, case law on the statute of repose, and how steel mill and auto plant exposure histories shape outcomes.
Pennsylvania Mesothelioma Verdicts and Settlements
Pennsylvania mesothelioma verdicts and 2025 legal developments, including the $3.8M Chirdon verdict, the Herold ruling, and Philadelphia mass-tort coordination.
Tennessee Mesothelioma Verdicts and Settlements
Tennessee mesothelioma verdicts: Stockton v. Ford, Davis in Maury County, Jackson in Hamilton County, plus Satterfield take-home precedent.
Georgia Mesothelioma Verdicts and Settlements
Key mesothelioma verdicts and settlement outcomes in Georgia, from shipyard exposure cases to manufacturing and paper mill claims.
Iowa Mesothelioma Verdicts and Settlements
Iowa mesothelioma litigation, including the Kinseth v. Weil-McLain $6.5M verdict reversed on appeal and the 2017 Chapter 686B framework.
New York Mesothelioma Verdicts and Settlements
Key mesothelioma verdicts and settlements in New York, including the $117M Durbec WTC verdict. NYCAL leads the nation in asbestos case volume.
Asbestos Trust Funds for Virginia Shipyard Workers and Navy Veterans
How Virginia shipyard workers, Navy veterans, and their families can file asbestos trust fund claims, including the C.E. Thurston & Sons Trust.
$45 Million and Counting: Illinois Mesothelioma Verdicts
Cook County leads the nation in mesothelioma jury awards. Key verdicts from 2023 to 2024 and what they mean for Illinois families.
Virginia Mesothelioma Verdicts and Settlements
Key Virginia mesothelioma verdicts from the $6.45M Parker case at Norfolk Naval Shipyard to the $17M Coulbourn verdict and the reversed Minton judgment.
Why Immunotherapy Works Differently in Peritoneal Mesothelioma
Nature study finds tumor location shapes immune environment, explaining why checkpoint therapy is less effective in peritoneal disease.
Asbestos Trust Funds for Maryland Workers
How Maryland shipyard, steel, and insulation workers file claims against the Porter Hayden, Wallace & Gale, and other asbestos trusts tied to the state.
Maryland Mesothelioma Verdicts and Settlements
Maryland mesothelioma case outcomes: the $1.56B Cherie Craft talc verdict, $14.5M Busch steamfitter case, and Dixon take-home Ford brake verdict.
Six Years of Mesothelioma Immunotherapy: From First Approval to 2026
From the 2020 CheckMate-743 approval to the 2025 BNT327 results, every major mesothelioma immunotherapy milestone in one timeline.
Blood Clot Biomarkers Could Predict Risk After Mesothelioma Surgery
Proteomics study identifies plasma protein markers that may predict which people with mesothelioma are at risk of blood clots after surgery.
Cohesin Gene Mutations Linked to Mesothelioma Recurrence After Surgery
Genomic study finds SMC3 and SMC1A mutations in multicystic peritoneal mesothelioma predict disease recurrence after cytoreductive surgery and HIPEC.
First ROS1 Fusion in Peritoneal Mesothelioma Responds to Crizotinib
First ROS1 gene fusion found in peritoneal mesothelioma. Patient achieved six months on crizotinib after immunotherapy failed.
Asbestos Trust Funds for Massachusetts Workers
How Massachusetts shipyard workers, textile mill workers, and construction tradespeople can file asbestos trust fund claims. Key trusts and process.
Asbestos Trust Funds for Minnesota Workers
How Minnesota taconite miners, Conwed fiberboard workers, and building tradespeople can file asbestos trust fund claims. Key trusts and process.
The Mesothelioma Treatment Landscape in 2026
Every major first-line, second-line, and investigational treatment for mesothelioma in 2026, with response rates, survival data, and trial status.
Massachusetts Mesothelioma Verdicts and Settlements
Massachusetts mesothelioma verdicts, including the $83M Lapointe v. AMACO Middlesex Superior verdict and the $42.6M Lovell talc verdict.
Minnesota Mesothelioma Verdicts and Settlements
Minnesota mesothelioma verdicts: the $65.5M Ramsey County talc verdict against J&J, Conwed ceiling tile cases, and Iron Range taconite claims.
First PITAC Procedure for Mesothelioma Performed in North America
A surgeon has performed the first pressurized aerosol chemotherapy (PITAC) for mesothelioma in North America, bringing a European innovation to U.S. patients.
TGF-β Combo Therapy Cuts Mesothelioma Tumor Growth by 70% in Lab Models
A 2026 study in Scientific Reports shows combined TGF-β inhibition reduced mesothelioma cell growth by up to 70% in preclinical models.
Asbestos Trust Funds for Connecticut Workers
How Connecticut submarine builders, brake plant workers, and helicopter plant workers can file asbestos trust fund claims. Key trusts and process.
Asbestos Trust Funds for Oregon Workers
How Oregon shipyard, mill, and construction workers can file asbestos trust fund claims. Key trusts, eligibility, and the filing process explained.
Connecticut Mesothelioma Verdicts and Settlements
Connecticut mesothelioma verdicts: $25M Plotkin J&J talc award, $22.5M Barone Vanderbilt verdict, and Electric Boat submarine cases from Bridgeport.
Oregon Mesothelioma Verdicts and Settlements
Key Oregon mesothelioma verdicts, from the $34.2M John Crane Portland shipyard case to the $260M J&J talc award and the Hoff and Sprague decisions.
8 Mesothelioma Trials Compared: Results Side by Side
Side by side results from CheckMate-743, KEYNOTE-483, ATOMIC-Meso, DREAM3R, CONFIRM, MARS 2, DENIM, and Hopkins periop.
Pelvic Mesothelioma Shrinks 83% With Immunotherapy
Frontiers in Oncology case study shows toripalimab plus chemotherapy produced major tumor reduction in rare pelvic mesothelioma.
Durvalumab Plus Chemo Doubles Meso Survival
Phase II PrE0505 trial shows durvalumab with pemetrexed-cisplatin yields 20.4-month median survival in unresectable pleural mesothelioma.
UK Trials Proton Beam Therapy for Mesothelioma
Phase III HIT-Meso trial compares proton beam therapy to surveillance across 23 UK centers, recruiting 148 people with pleural mesothelioma.
Hawaii Identifies L-BAM, Treatable Mesothelioma
UH Cancer Center researchers discover a genetic mesothelioma variant caused by BAP1 mutations, not asbestos, that responds to standard treatment.
CheckMate-743 at Five Years: 14% Still Alive
Five-year data from CheckMate-743 shows 14% survival with nivolumab plus ipilimumab vs 6% with chemotherapy. Non-epithelioid benefit is striking.
DREAM3R: Durvalumab Plus Chemo Falls Short
DREAM3R Phase 3 trial of durvalumab plus chemotherapy for pleural mesothelioma stopped early due to enrollment challenges. A 58% response rate, but no proof.
Baylor-Duke NEMO Trial Tests Immuno Before Surgery
NEMO trial at Baylor and Duke is recruiting people with operable pleural mesothelioma to test chemoimmunotherapy before surgery.
Blood Test Predicts Immunotherapy Response in Meso
Georgetown-Hopkins Phase 2 trial shows ctDNA blood test predicts which people with mesothelioma benefit from immunotherapy before surgery.
Mount Sinai P/D Surgery: Zero Mortality in Study
Mount Sinai reports zero perioperative mortality for pleurectomy/decortication in mesothelioma, challenging MARS2 trial skepticism.
UCSF Proposes First Peritoneal Meso Staging System
Dr. Mohamed Adam's survival tree model uses mitotic rate, PCI, and histology to stage peritoneal mesothelioma and guide CRS-HIPEC decisions.
Checkpoint Inhibitors for Mesothelioma: FDA Options
FDA-approved nivolumab plus ipilimumab improves mesothelioma survival. Learn how checkpoint inhibitors work, side effects, and who benefits.
Genetic Testing for Mesothelioma: What to Know
Genetic testing for mesothelioma including BAP1, CDKN2A, and NGS panels. How results guide treatment decisions and clinical trial eligibility.
Rare Mesothelioma Cell Types: Variants and Care
Rare mesothelioma cell types: desmoplastic, lymphohistiocytoid, deciduoid, and WDPM variants. Diagnosis challenges and prognosis.
Targeted Therapy for Mesothelioma: 2026 Guide
Targeted therapy options for mesothelioma including BAP1, NF2, and TEAD inhibitors. Current clinical trials and who may benefit.
ADI-PEG20 Phase 3 Trial Shows Promise: ATOMIC-Meso Results
ATOMIC-Meso Phase 3 trial shows ADI-PEG20 plus chemotherapy improves survival in pleural mesothelioma. Analysis of this arginine-depleting therapy.
Ikena Halts IK-930 TEAD Inhibitor Program
Ikena discontinued IK-930 in May 2024 after disappointing Phase 1 data in NF2-mutated tumors including mesothelioma. Other TEAD inhibitors advance.
UV1 Vaccine Gets FDA Fast Track for Mesothelioma
FDA grants Fast Track to UV1 telomerase vaccine for mesothelioma. Combined with immunotherapy, UV1 showed 64% response rate in trials.
Atezolizumab Trial: Phase 1 Study for Mesothelioma
Cancer Research UK PHASE1/PHASE2 clinical trial testing atezolizumab (Tecentriq) for people with mesothelioma. Trial NCT05944237 is now recruiting.
Atezolizumab Phase 3 Trial for Pleural Mesothelioma
PHASE3 clinical trial testing atezolizumab (Tecentriq) for mesothelioma. Trial NCT04996017 is recruiting.
Atezolizumab Phase 1 Trial for Pleural Mesothelioma
University Hospital, Antwerp PHASE1/PHASE2 clinical trial testing atezolizumab (Tecentriq) for people with mesothelioma. Trial NCT05765084 is now recruiting.
A2 Bio BASECAMP-1 Screening Study (NCT04981119)
A2 Biotherapeutics Inc. observational prescreening study collecting cells from solid tumor patients for future CAR-T manufacturing. NCT04981119.
A2 Bio EVEREST-2 CAR-T Phase 1/2 Trial (NCT06051695)
A2 Biotherapeutics EVEREST-2 Phase 1/2 trial of A2B694, a logic-gated Tmod CAR-T targeting mesothelin-positive solid tumors including mesothelioma.
NCI TNhYP218 CAR-T Phase 1 Trial (NCT06885697)
National Cancer Institute Phase 1 trial of TNhYP218, an anti-mesothelin CAR-T, for mesothelin-expressing solid tumors including mesothelioma.
CAR-T Trial: Phase 1 Study for Pleural Mesothelioma
Suzhou Maximum Bio-tech Co. Ltd. Phase 1 trial of MT027, a B7-H3 targeted CAR-T delivered intrapleurally for pleural malignant tumors. NCT06726564.
UTC CAR-T Phase 1 Trial (NCT06256055)
UTC Therapeutics Phase 1 trial of UCMYM802, a circular-mRNA anti-mesothelin CAR-T for mesothelin-positive solid tumors including mesothelioma.
Immunotherapy Trial: Phase 1 Study for Mesothelioma
Baylor College of Medicine PHASE1/PHASE2 clinical trial testing immunotherapy for people with mesothelioma. Trial NCT05932199 is now recruiting.
NCI HIPEC Phase 1 Trial (NCT04847063)
PHASE1 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma. Trial NCT04847063 is recruiting.
NCI HIPEC Phase 2 Trial (NCT05001880)
PHASE2 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma. Trial NCT05001880 is recruiting.
MSK HIPEC Phase 2 Trial (NCT06057935)
PHASE2 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma. Trial NCT06057935 is recruiting.
TIL Cell Therapy Phase 2 Trial (NCT03935893)
UPMC Hillman Cancer Center Phase 2 clinical trial testing autologous TIL cell therapy for people with mesothelioma. Trial NCT03935893 is recruiting.
BWH MAGIC AKI Phase 2 Trial (NCT05730816)
Brigham and Women's Hospital Phase 2 trial testing IV magnesium to prevent kidney injury during HIOC cisplatin surgery for mesothelioma (NCT05730816).
NCI FAPI-74 PET Imaging Phase 2 Trial (NCT06503146)
National Cancer Institute Phase 2 imaging trial evaluating [18F]FAPI-74 PET scans for cancer detection, including mesothelioma (NCT06503146).
MSK Sacituzumab Govitecan Phase 2 Trial (NCT06477419)
Memorial Sloan Kettering Phase 2 trial of sacituzumab govitecan for previously treated diffuse pleural mesothelioma (NCT06477419) is recruiting.
Mesothelioma Clinical Trials Recruiting in 2026
Approximately 90 mesothelioma trials are recruiting in 2026. We profile active CAR-T, CAR-NK, bispecific, and surgery trials from ClinicalTrials.gov.
Nivolumab + Ipilimumab Phase 1/2 Trial (NCT04665206)
Vivace Therapeutics, Inc PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT04665206 is now recruiting.
Nivolumab + Ipilimumab Phase 2 Trial for Mesothelioma
Alliance phase 2 trial testing nivolumab + ipilimumab for mesothelioma. NCT05647265 is now recruiting patients.
Nivolumab + Ipilimumab Phase 1/2 Trial (NCT06362369)
7 Hills Pharma, LLC PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT06362369 is now recruiting.
Nivolumab + Ipilimumab Trial: Study for Mesothelioma
Istituto Oncologico Veneto IRCCS N/A clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT06581549 is now recruiting.
Nivolumab + Ipilimumab Phase 2 Trial (NCT04400539)
University Hospital, Lille PHASE2 clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT04400539 is now recruiting.
Nivolumab + Ipilimumab Phase 1/2 Trial (NCT07121374)
University Hospital, Antwerp PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT07121374 is now recruiting.
VM Oncology Pembrolizumab Phase 1/2 (NCT03556228)
VM Oncology, LLC PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT03556228 is now recruiting.
MSK Pembrolizumab Phase 1 Trial (NCT04897022)
Memorial Sloan Kettering Cancer Center PHASE1 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT04897022 is now recruiting.
Medicenna Pembrolizumab Phase 1/2 (NCT05086692)
Medicenna Therapeutics, Inc. PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT05086692 is now recruiting.
Genmab Pembrolizumab Phase 1/2 (NCT05579366)
Genmab PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT05579366 is now recruiting.
Tango Pembrolizumab Phase 1/2 Trial (NCT05732831)
Tango Therapeutics, Inc. PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT05732831 is now recruiting.
KaliVir Pembrolizumab Phase 1 (NCT06444815)
KaliVir Immunotherapeutics PHASE1 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT06444815 is now recruiting.
Pembrolizumab Phase 2 Trial for Pleural Mesothelioma
Hyogo Medical University PHASE2 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT06318286 is now recruiting.
Volrustomig (MEDI5752) Phase 3 Trial in Pleural Mesothelioma (NCT06097728)
AstraZeneca's volrustomig (MEDI5752), a PD-1/CTLA-4 bispecific antibody, in a global Phase 3 trial vs platinum-pemetrexed or nivolumab + ipilimumab.
Hopkins: Immunotherapy + Surgery Extends Survival
Johns Hopkins trial shows pre/post-surgery nivolumab + ipilimumab safe for operable mesothelioma, with 28.6-month median survival.
New Review Maps BAP1 Loss in Mesothelioma
New Oncogene review maps BAP1 loss mechanisms in mesothelioma. 65% of cases involve BAP1 inactivation; EZH2 inhibitors emerge as potential targeted therapy.
Cell Therapy Shrinks Tumors in 63%
A new cell therapy achieved tumor shrinkage in 63% of advanced mesothelioma patients. More than double typical response rates.
Measles Vaccine Gets FDA Orphan Drug for Meso
French biotech Oncovita receives FDA orphan drug designation for MVdeltaC, a modified measles virus showing 60-70% tumor reduction in mesothelioma models.
Mesothelioma Treatment Advances: 2025
2025 saw major mesothelioma treatment advances including TEAD inhibitors, bispecific antibodies, and perioperative immunotherapy. Here's the full review.
Drug Combo Achieves 60% Response Rate
A Dutch trial found two drugs achieved a 60% response rate in mesothelioma patients whose cancer returned after immunotherapy.
One Drug Halted, Another Advances
Novartis halted one experimental mesothelioma drug, but a competitor's TEAD inhibitor shows strong results in clinical trials.
Cyncado to Test TT-4 in Australian Meso Trial
An Australian trial will test Cyncado's TT-4 A2B receptor antagonist in ~50 people with mesothelioma after first-line therapy.
Mesothelioma FAQ: Common Questions
Honest answers to common questions about mesothelioma diagnosis, prognosis, treatment options, legal rights, and caregiving. Based on real patient concerns.
Drywall Workers and Asbestos Exposure
Drywall workers face mesothelioma risk from asbestos in joint compound used until 1977. Studies found 59% of workers had lung changes from exposure.
Mesothelioma Survival: 18-Year Survivor's Story
Diagnosed with peritoneal mesothelioma at 21 while pregnant, Tamron Little shares her 18-year journey and the reality of long-term survivorship.
The BAP1 Breakthrough: L-BAM Discovery
Dr. Michele Carbone's team identified L-BAM. A genetic form of mesothelioma with dramatically better outcomes than asbestos-related disease.
Steel Mill Workers and Asbestos Risks
Steel mill workers face elevated mesothelioma risk from asbestos used to protect against extreme heat. Studies show 2-4x higher disease rates.
Mesothelioma Awareness Day: September 26
September 26 is Mesothelioma Awareness Day. Learn about the history of awareness efforts, current statistics, and how to get involved.
Mesothelioma Treatment: Hopkins Immunotherapy Trial
Johns Hopkins phase 2 trial shows pre- and post-surgery immunotherapy is safe and effective for operable mesothelioma, with 28.6-month median survival.
Power Plant Workers: Asbestos Exposure Risk
Power plant workers face elevated mesothelioma rates from asbestos in boilers, turbines, and piping. Studies show 3-8x higher disease rates.
VT3989 Doubles Time Without Progression
Patients on VT3989 went 40 weeks without cancer progression. Vs. 15 weeks on standard chemo. FDA granted Fast Track status.
Hopkins: Pre-Surgery Immunotherapy Success
A Johns Hopkins trial found that immunotherapy before and after surgery extended median survival to 28.6 months, 10 months longer than average.
Trial Tests Immunotherapy Before Surgery
Baylor and Duke are testing immunotherapy before surgery for mesothelioma. Trial now enrolling operable patients.
IMPALA Trial: Light Therapy for Mesothelioma
The IMPALA trial in France is testing intrapleural photodynamic therapy combined with nivolumab for inoperable mesothelioma. Results expected mid-2026.
Textile Workers and Asbestos Exposure
Textile mill workers who manufactured asbestos cloth, rope, and fireproof fabrics face extremely high mesothelioma rates. Learn about exposure sources.
Oil Refinery Workers and Asbestos Risks
Oil refinery workers face elevated mesothelioma risk from asbestos insulation throughout refineries. Studies show 2-5x higher disease rates.
Railroad Workers and Asbestos Exposure Risks
Railroad workers face elevated mesothelioma risk from asbestos in locomotives, brake systems, and rail facilities. FELA provides unique legal options.
Paul Kraus: 27-Year Mesothelioma Survivor
Paul Kraus defied expectations for 27 years, becoming the world's longest-living mesothelioma survivor and patient advocate.
Teachers and School Staff: Asbestos Risk
Teachers and school staff face asbestos exposure from deteriorating building materials. EPA data shows 45,000+ schools contain asbestos.
HVAC Technicians and Asbestos Risks
HVAC workers face mesothelioma risk from asbestos in duct insulation, boilers, and old equipment. Learn about exposure sources and protection.
Dual-Target Immunotherapy Shows 52% Response
BioNTech's dual-target immunotherapy achieved a 52% response rate in people with mesothelioma. Results presented at ASCO 2025.
Genetic Factors in Mesothelioma Risk
While asbestos causes most mesothelioma, genetic factors like BAP1 mutations and Lynch syndrome can increase risk. Learn what genetics reveal.
Auto Mechanics and Asbestos: Brake Dust Risk
Auto mechanics face mesothelioma risk from asbestos in brake pads and clutches. Learn about exposure history, current risks, and protection.
Mesothelioma Diet & Nutrition Guide
Proper nutrition supports mesothelioma treatment outcomes. Learn about caloric needs, protein requirements, and managing treatment side effects.
Getting a Second Opinion for Mesothelioma
Mesothelioma is rare and often misdiagnosed. Learn why getting a second opinion is crucial and how to find specialized mesothelioma experts.
Dr. Harvey Pass: Biomarker Pioneer
Dr. Harvey Pass has led the search for mesothelioma biomarkers. Blood tests that could detect the disease when treatment is most effective.
Mesothelioma Staging: TNM System Guide
Mesothelioma staging determines treatment options and prognosis. Learn about the TNM system, survival rates by stage, and what staging means for you.
Choosing a Mesothelioma Treatment Center
Mesothelioma requires specialized care. Learn what makes a treatment center qualified and how to find the right team for your diagnosis.
Mesothelioma Caregiver Guide for Families
Caregiving for a mesothelioma patient is demanding. Learn practical tips for managing symptoms, appointments, emotions, and your own well-being.
FDA Approves Opdivo Qvantig for Mesothelioma
FDA approval of Opdivo Qvantig allows subcutaneous nivolumab delivery in under 5 minutes, compared to 30-minute IV infusions for people with mesothelioma.
Wittenoom: Australia's Blue Asbestos Ghost Town
Australia's Wittenoom mining town became the nation's deadliest industrial disaster. More than 2,000 people have died from asbestos exposure.
Paul Gleason: Breakfast Club Actor's Mesothelioma
Actor Paul Gleason, best known as Principal Vernon in The Breakfast Club, died of pleural mesothelioma in 2006, three weeks after diagnosis.
KEYNOTE-483: Keytruda Combo Approved
KEYNOTE-483 Phase 3 trial shows pembrolizumab plus chemotherapy improves survival to 17.3 months. FDA approved September 2024 for first-line treatment.
FDA Approves Keytruda Combo for Mesothelioma
The FDA approved pembrolizumab (Keytruda) with chemotherapy for advanced pleural mesothelioma, showing a 21% reduction in death risk in the KEYNOTE-483 trial.
Multimodal Mesothelioma Treatment Guide
Multimodal therapy doubles mesothelioma survival rates. Trimodal protocols, HIPEC for peritoneal, and patient selection criteria explained.
Leonard Bernstein: The Maestro's Final Years
Leonard Bernstein, creator of West Side Story and conductor of the New York Philharmonic, battled lung disease including a pleural tumor in his final years.
Dr. David Sugarbaker: Mesothelioma Pioneer
Dr. David Sugarbaker's contributions to mesothelioma surgery and training continue to shape how the disease is treated worldwide.
DENIM Trial: Vaccine Did Not Extend Survival
The Phase 2/3 DENIM trial found that dendritic cell vaccination did not extend overall survival for people with mesothelioma after chemotherapy.
Merlin Olsen: NFL Legend's Mesothelioma
Hall of Fame defensive tackle Merlin Olsen, 14-time Pro Bowler and actor, died of mesothelioma in 2010 after asbestos exposure from childhood construction work.
MARS 2: Chemo Outperformed Surgery
The landmark MARS 2 trial found that chemotherapy alone led to better survival than surgery plus chemotherapy for people with pleural mesothelioma.
ATOMIC-Meso: Quadrupled 3-Year Survival
The ATOMIC-Meso trial showed pegargiminase plus chemotherapy quadrupled 3-year survival rates in nonepithelioid mesothelioma, the most aggressive subtype.
CONFIRM Trial: Nivolumab Extends Survival in Relapsed Mesothelioma
CONFIRM (Phase 3, 332 patients) showed nivolumab improved median OS to 10.2 vs 6.9 months in relapsed mesothelioma. PD-L1 did not predict benefit.
Warren Zevon: 'Enjoy Every Sandwich'
Warren Zevon's final months remain a powerful example of facing mortality with honesty and creativity after his mesothelioma diagnosis.
SynKIR-110 CAR-T Gets FDA Fast-Track
FDA grants fast-track to SynKIR-110 CAR-T therapy for mesothelioma. Phase 1 trial recruiting at MD Anderson, Penn, and more.
CAR-T Cell Therapy for Mesothelioma
CAR-T cells target mesothelin on mesothelioma cells. SynKIR-110 received FDA fast-track designation in April 2023. Multiple trials recruiting.
FDA OKs Opdivo+Yervoy for Mesothelioma
In October 2020, the FDA approved nivolumab plus ipilimumab as the first immunotherapy for mesothelioma, marking the first new treatment in 16 years.
Mesothelioma Immunotherapy: FDA Options
Nivolumab plus ipilimumab improves survival to 18 months. See FDA-approved immunotherapies and current clinical trials.
CheckMate-743: Immunotherapy Beats Chemo
CheckMate-743 trial shows nivolumab plus ipilimumab extends median survival to 18.1 months vs 14.1 months with chemotherapy. 3-year survival doubles.
Checkpoint Inhibitors for Mesothelioma
Checkpoint inhibitors like nivolumab and pembrolizumab release the brakes on the immune system. Learn how PD-1 and CTLA-4 blockers treat mesothelioma.
Mesothelioma Second-Line Treatment Options
When first-line chemo fails, second-line options include gemcitabine, immunotherapy combinations, and clinical trials. PEMMELA trial showed 60% response.
Mesothelioma Clinical Trials Guide
Guide to finding mesothelioma clinical trials on ClinicalTrials.gov. Active studies include CAR-T therapy, immunotherapy combinations, and targeted drugs.
FDA Approves Optune Lua for Mesothelioma
In May 2019, the FDA approved the NovoTTF-100L System (Optune Lua) for mesothelioma, the first new treatment option since pemetrexed in 2004.
TTFields for Mesothelioma: Optune Lua
Tumor Treating Fields (Optune Lua) is FDA-approved for mesothelioma. Uses electric fields to disrupt cancer cell division with minimal side effects.
Mesothelioma in Women: Survival Rates
Women with mesothelioma have 3x better 5-year survival than men. 91% of female cases are from secondary household asbestos exposure.
Mesothelioma Chemotherapy: Drugs and Response
Pemetrexed plus cisplatin extends median survival to 12.1 months. Response rates vary by cell type: epithelioid 16.5 months vs sarcomatoid 8.8 months.
Mesothelioma Misdiagnosis: 22.6% Missed
22.6% of people with mesothelioma are initially misdiagnosed. Learn common conditions it's confused with and why second opinions matter.
HIPEC for Peritoneal Mesothelioma: Survival
CRS/HIPEC achieves 53-103 month median survival for peritoneal mesothelioma. 28-year data shows 43.6% cure rate for 7+ year survivors.
Pericardial Mesothelioma: Rare Heart Cancer
Pericardial mesothelioma affects the heart lining and accounts for less than 1% of cases. Learn about symptoms, diagnosis challenges, and treatment options.
Testicular Mesothelioma: Rarest Form
Testicular mesothelioma affects less than 1% of patients but has the best prognosis. 49% five-year survival, symptoms, treatment, and outlook.
Mesothelioma Blood Tests & Biomarkers
MESOMARK blood test detects elevated SMRP levels in mesothelioma. Learn about biomarkers for monitoring and early detection research.
Mesothelioma Radiation Therapy: IMRT Guide
Radiation therapy can control tumor growth and relieve symptoms for people with mesothelioma. Learn about IMRT, when radiation is used, and what to expect.
Mesothelioma Palliative Care Guide
Palliative care improves quality of life for people with mesothelioma. Learn about symptom management, hospice eligibility, and support options.
Mesothelioma Cell Types Explained
Cell type determines mesothelioma prognosis. Epithelioid has best outcomes (~70% of cases). Learn how histology affects treatment response.
Mesothelioma Surgery: P/D vs EPP Options
Surgery can extend survival for eligible people with mesothelioma. Compare pleurectomy/decortication and extrapleural pneumonectomy options.
Mesothelioma Diagnosis: 65% Found Late
65% of mesothelioma cases are diagnosed at Stage 3 or 4. Learn how staging works, survival rates by stage, and why early detection triples survival time.
Mesothelioma Prognosis & Life Expectancy
Mesothelioma prognosis depends on stage, cell type, and treatment. Learn what factors influence survival and how to improve your outlook.
Mesothelioma Treatment Options Overview
Complete guide to mesothelioma treatment options. Multimodal treatment achieves 32-month median survival. Learn about surgery, chemo, and immunotherapy.
Mesothelioma Symptoms: Early Warning Signs
Mesothelioma symptoms often mimic common conditions. Learn the warning signs of pleural, peritoneal, and other types. Early detection improves survival.
Peritoneal Mesothelioma: 50% Survival Rates
Peritoneal mesothelioma affects the abdominal lining. With HIPEC surgery, 5-year survival reaches 47-52%. Learn symptoms, treatment, and prognosis.
Pleural Mesothelioma: Symptoms & Treatment
Pleural mesothelioma accounts for 81% of US cases (CDC 2003-2022). Learn about symptoms, staging, treatment options, and SEER 5-year survival of 12%.
Mesothelioma Causes & Risk Factors
Asbestos exposure is the only proven cause of mesothelioma. Learn how asbestos fibers cause cancer, who is at risk, and the 20-50 year latency period.
What is Mesothelioma?
Mesothelioma is a rare cancer caused by asbestos. Learn about types, symptoms, causes, and survival rates from independent medical sources.
BAP1 Gene Mutation and Mesothelioma
BAP1 germline mutations raise mesothelioma risk after low asbestos exposure. Testa 2011 (PMID 21874000) anchors the syndrome.